Incyte Corporation (INCY) 10-Year Financial Performance & Capital Metrics

INCY • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutIncyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.Show more

Revenue $4.24B +14.8%
EBITDA $169M -76.9%
Net Income $33M -94.5%
EPS (Diluted) 0.15 -94.3%
Gross Margin 91.09% -0.4%
EBITDA Margin 3.99% -79.9%
Operating Margin 1.89% -89.3%
Net Margin 0.77% -95.2%
ROE 0.76% -94.0%
ROIC 3.15% -88.8%
Debt/Equity 0.01 +71.2%
Interest Coverage 35.15 -86.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 81 (top 19%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 14.5%
✓Share count reduced 6.8% through buybacks

✗Weaknesses

✗Profits declining 40.8% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.56%

5Y14.46%

3Y12.41%

TTM18.09%

Profit (Net Income) CAGR

10Y-

5Y-40.76%

3Y-67.48%

TTM3559.21%

EPS CAGR

10Y-

5Y-40.73%

3Y-67.25%

TTM4164.29%

ROCE

10Y Avg6.96%

5Y Avg7.62%

3Y Avg9.38%

Latest1.72%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	753.75M	1.11B	1.54B	1.88B	2.16B	2.67B	2.99B	3.39B	3.7B	4.24B
Revenue Growth %	0.47%	0.47%	0.39%	0.23%	0.15%	0.24%	0.12%	0.14%	0.09%	0.15%
Cost of Goods Sold+	49.41M	104.01M	110.16M	127.59M	147.28M	161.63M	187.34M	253.35M	315.15M	377.72M
COGS % of Revenue	0.07%	0.09%	0.07%	0.07%	0.07%	0.06%	0.06%	0.07%	0.09%	0.09%
Gross Profit+	704.34M	1B	1.43B	1.75B	2.01B	2.51B	2.8B	3.14B	3.38B	3.86B
Gross Margin %	0.93%	0.91%	0.93%	0.93%	0.93%	0.94%	0.94%	0.93%	0.91%	0.91%
Gross Profit Growth %	0.51%	0.42%	0.42%	0.23%	0.15%	0.25%	0.12%	0.12%	0.08%	0.14%
Operating Expenses+	653.69M	837.69M	1.66B	1.6B	1.59B	2.75B	2.16B	2.54B	2.73B	3.78B
OpEx % of Revenue	0.87%	0.76%	1.08%	0.85%	0.74%	1.03%	0.72%	0.75%	0.74%	0.89%
Selling, General & Admin	174.17M	255.83M	335.61M	400.94M	435.68M	516.9M	703.22M	955.78M	1.1B	1.18B
SG&A % of Revenue	0.23%	0.23%	0.22%	0.21%	0.2%	0.19%	0.24%	0.28%	0.3%	0.28%
Research & Development	479.51M	581.86M	1.33B	1.2B	1.15B	2.22B	1.46B	1.59B	1.63B	2.61B
R&D % of Revenue	0.64%	0.53%	0.86%	0.64%	0.53%	0.83%	0.49%	0.47%	0.44%	0.61%
Other Operating Expenses	0	0	0	0	0	12.52M	0	0	0	0
Operating Income+	50.65M	164.02M	-235.68M	155.4M	421.69M	-240.29M	637.54M	599.56M	651.77M	80.14M
Operating Margin %	0.07%	0.15%	-0.15%	0.08%	0.2%	-0.09%	0.21%	0.18%	0.18%	0.02%
Operating Income Growth %	11.54%	2.24%	-2.44%	1.66%	1.71%	-1.57%	3.65%	-0.06%	0.09%	-0.88%
EBITDA+	95.53M	222.44M	-183.5M	210.37M	476.22M	-188.48M	695.38M	667.42M	734.43M	169.39M
EBITDA Margin %	0.13%	0.2%	-0.12%	0.11%	0.22%	-0.07%	0.23%	0.2%	0.2%	0.04%
EBITDA Growth %	1.61%	1.33%	-1.82%	2.15%	1.26%	-1.4%	4.69%	-0.04%	0.1%	-0.77%
D&A (Non-Cash Add-back)	44.88M	58.42M	52.18M	54.97M	54.53M	51.81M	57.84M	67.86M	82.66M	89.25M
EBIT	53.16M	146.15M	-305.39M	116.89M	488.65M	-230.04M	572.35M	531.78M	836.77M	318.91M
Net Interest Income+	-40.31M	-34.13M	-6.9M	-1.54M	-1.85M	-2.17M	-1.91M	-2.67M	-2.55M	126.43M
Interest Income	5.29M	4.61M	0	0	0	0	0	0	0	128.71M
Interest Expense	45.6M	38.74M	6.9M	1.54M	1.85M	2.17M	1.91M	2.67M	2.55M	2.28M
Other Income/Expense	-43.09M	-56.62M	-76.61M	-40.05M	65.1M	8.07M	-67.09M	-70.45M	182.44M	236.49M
Pretax Income+	7.56M	107.4M	-312.29M	115.35M	486.79M	-232.22M	570.44M	529.12M	834.22M	316.63M
Pretax Margin %	0.01%	0.1%	-0.2%	0.06%	0.23%	-0.09%	0.19%	0.16%	0.23%	0.07%
Income Tax+	1.02M	3.18M	852K	5.85M	39.88M	63.48M	-378.14M	188.46M	236.62M	284.01M
Effective Tax Rate %	0.86%	0.97%	1%	0.95%	0.92%	1.27%	1.66%	0.64%	0.72%	0.1%
Net Income+	6.53M	104.22M	-313.14M	109.49M	446.91M	-295.7M	948.58M	340.66M	597.6M	32.62M
Net Margin %	0.01%	0.09%	-0.2%	0.06%	0.21%	-0.11%	0.32%	0.1%	0.16%	0.01%
Net Income Growth %	1.13%	14.96%	-4%	1.35%	3.08%	-1.66%	4.21%	-0.64%	0.75%	-0.95%
Net Income (Continuing)	6.53M	104.22M	-313.14M	109.49M	446.91M	-295.7M	948.58M	340.66M	597.6M	32.62M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.03	0.54	-1.53	0.51	2.05	-1.36	4.27	1.52	2.65	0.15
EPS Growth %	1.1%	17%	-3.83%	1.33%	3.02%	-1.66%	4.14%	-0.64%	0.74%	-0.94%
EPS (Basic)	0.04	0.55	-1.53	0.52	2.08	-1.36	4.30	1.53	2.67	0.16
Diluted Shares Outstanding	187.3M	194.13M	204.58M	215.63M	217.66M	218.07M	222.07M	223.96M	225.93M	210.53M
Basic Shares Outstanding	179.6M	187.87M	204.58M	212.38M	214.91M	218.07M	220.43M	222M	223.63M	207.11M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	842.38M	994.18M	1.5B	1.83B	2.48B	2.36B	3.12B	4.09B	4.65B	3.24B
Cash & Short-Term Investments	707.78M	808.55M	1.17B	1.44B	2.12B	1.8B	2.35B	3.24B	3.66B	2.16B
Cash Only	521.44M	652.34M	899.51M	1.16B	1.83B	1.51B	2.06B	2.95B	3.21B	1.69B
Short-Term Investments	186.34M	156.2M	270.14M	274.34M	284.87M	288.37M	290.75M	287.54M	442.67M	470.26M
Accounts Receivable	114.45M	148.76M	266.3M	307.6M	308.81M	481.99M	616.3M	644.88M	743.56M	853.15M
Days Sales Outstanding	55.42	49.11	63.27	59.66	52.21	65.97	75.33	69.34	73.44	73.42
Inventory	1.78M	4.11M	6.48M	6.97M	11.4M	16.43M	27.9M	41.99M	62.97M	58.87M
Days Inventory Outstanding	13.17	14.41	21.48	19.93	28.25	37.09	54.37	60.5	72.93	56.89
Other Current Assets	516K	0	0	0	0	0	0	167.01M	182.83M	168.91M
Total Non-Current Assets+	165.06M	644.42M	797.73M	813.51M	945.26M	1.2B	1.81B	1.75B	2.14B	2.21B
Property, Plant & Equipment	86.01M	167.68M	259.76M	319.75M	406.63M	588.08M	751.47M	765.61M	777.05M	794.21M
Fixed Asset Turnover	8.76x	6.59x	5.91x	5.89x	5.31x	4.53x	3.97x	4.43x	4.76x	5.34x
Goodwill	0	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M
Intangible Assets	0	270.44M	236.9M	215.36M	193.83M	172.29M	150.75M	129.22M	123.55M	113.8M
Long-Term Investments	35.25M	31.99M	134.36M	99.2M	133.66M	222.3M	221.27M	133.68M	187.72M	18.81M
Other Non-Current Assets	43.81M	18.72M	11.12M	23.6M	55.56M	60.71M	68.06M	106.1M	260.92M	360.8M
Total Assets+	1.01B	1.64B	2.3B	2.65B	3.43B	3.56B	4.93B	5.84B	6.78B	5.44B
Asset Turnover	0.75x	0.67x	0.67x	0.71x	0.63x	0.75x	0.61x	0.58x	0.54x	0.78x
Asset Growth %	0.21%	0.63%	0.41%	0.15%	0.3%	0.04%	0.39%	0.18%	0.16%	-0.2%
Total Current Liabilities+	168.01M	273.5M	375.4M	425.28M	513.34M	631.2M	854.31M	1.16B	1.24B	1.64B
Accounts Payable	30.09M	75.6M	67.67M	103.83M	83.65M	98.77M	172.11M	277.55M	109.6M	197.47M
Days Payables Outstanding	222.23	265.29	224.22	297.02	207.3	223.03	335.34	399.86	126.94	190.82
Short-Term Debt	0	0	7.39M	0	18.3M	0	0	0	0	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	38.12M	70.44M	158.88M	171.36M	226.72M	260.06M	328.26M	435.86M	545.01M	724.83M
Current Ratio	5.01x	3.64x	4.01x	4.31x	4.83x	3.74x	3.65x	3.54x	3.75x	1.97x
Quick Ratio	5.00x	3.62x	3.99x	4.29x	4.81x	3.71x	3.62x	3.50x	3.69x	1.94x
Cash Conversion Cycle	-153.63	-201.78	-139.48	-217.43	-126.83	-119.97	-205.64	-270.02	19.43	-60.5
Total Non-Current Liabilities+	668.28M	945.63M	296.56M	294.52M	315M	318.45M	309.04M	313.79M	351.89M	354.85M
Long-Term Debt	619.89M	651.48M	16.61M	17.43M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	31.92M	32.57M	31.63M	30.08M	29.16M	33.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	48.38M	294.15M	279.95M	277.08M	283.09M	285.88M	277.41M	283.7M	322.73M	321.31M
Total Liabilities	836.28M	1.22B	671.95M	719.79M	828.34M	949.65M	1.16B	1.47B	1.59B	2B
Total Debt+	619.89M	651.48M	24M	36.13M	60.23M	47.53M	44.82M	41.46M	38.29M	43.54M
Net Debt	98.45M	-862K	-875.51M	-1.13B	-1.77B	-1.47B	-2.01B	-2.91B	-3.18B	-1.64B
Debt / Equity	3.62x	1.55x	0.01x	0.02x	0.02x	0.02x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	6.49x	2.93x	-	0.17x	0.13x	-	0.06x	0.06x	0.05x	0.26x
Net Debt / EBITDA	1.03x	-0.00x	-	-5.36x	-3.72x	-	-2.89x	-4.36x	-4.32x	-9.71x
Interest Coverage	1.11x	4.23x	-34.16x	100.71x	227.33x	-110.53x	334.14x	224.89x	255.50x	35.15x
Total Equity+	171.16M	419.47M	1.63B	1.93B	2.6B	2.61B	3.77B	4.37B	5.19B	3.45B
Equity Growth %	3.1%	1.45%	2.89%	0.18%	0.35%	0%	0.44%	0.16%	0.19%	-0.34%
Book Value per Share	0.91	2.16	7.97	8.93	11.94	11.97	16.98	19.51	22.97	16.38
Total Shareholders' Equity	171.16M	419.47M	1.63B	1.93B	2.6B	2.61B	3.77B	4.37B	5.19B	3.45B
Common Stock	187K	189K	211K	213K	216K	219K	221K	223K	224K	193K
Retained Earnings	-1.78B	-1.67B	-1.99B	-1.88B	-1.43B	-1.73B	-777.87M	-437.21M	160.38M	-1.07B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-809K	-2.89M	-7.01M	-10.16M	-15.54M	-15.36M	-19.45M	15.07M	13.11M	-13.12M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	86.54M	304.76M	-92.99M	336.23M	710.66M	-124.6M	749.49M	969.94M	496.49M	335.34M
Operating CF Margin %	0.11%	0.28%	-0.06%	0.18%	0.33%	-0.05%	0.25%	0.29%	0.13%	0.08%
Operating CF Growth %	2.3%	2.52%	-1.31%	4.62%	1.11%	-1.18%	7.02%	0.29%	-0.49%	-0.32%
Net Income	6.53M	104.22M	-313.14M	109.49M	446.91M	-295.7M	948.58M	340.66M	597.6M	32.62M
Depreciation & Amortization	44.88M	58.42M	52.18M	54.97M	54.53M	51.81M	57.84M	67.86M	82.66M	89.25M
Stock-Based Compensation	69.87M	96.2M	133.06M	148.15M	166.59M	177.88M	183.01M	188.42M	215.89M	266.06M
Deferred Taxes	1.71M	3.26M	91.16M	-459K	-377K	-350K	-465.6M	57.09M	-158.9M	-85.55M
Other Non-Cash Items	-1.61M	17.89M	7.99M	70.61M	-14.29M	13.51M	40.23M	117.11M	7.89M	-105.28M
Working Capital Changes	-34.85M	24.75M	-64.23M	-46.54M	57.3M	-71.74M	-14.57M	198.81M	-248.65M	138.24M
Change in Receivables	-56.52M	-23.95M	-117.54M	-41.3M	-1.21M	-173.19M	-134.31M	-28.58M	-98.68M	-111.59M
Change in Inventory	98K	4.05M	4.85M	4.04M	-6.1M	-19.47M	-20.96M	-67.5M	-170.15M	-127.63M
Change in Payables	5.62M	43.76M	-7.93M	36.16M	-20.18M	15.12M	73.34M	105.44M	-167.94M	88.16M
Cash from Investing+	-105.01M	-232.49M	-349.98M	-86.42M	-87.45M	-269M	-207.7M	-78.54M	-207.68M	157.52M
Capital Expenditures	-26M	-120.28M	-111.02M	-73.48M	-78.06M	-187.38M	-181.01M	-77.83M	-47.49M	-86.26M
CapEx % of Revenue	0.03%	0.11%	0.07%	0.04%	0.04%	0.07%	0.06%	0.02%	0.01%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-26M	30.64M	-111.02M	-73.48M	-78.06M	-187.38M	-181.01M	-709K	-47.49M	-13.9M
Cash from Financing+	87.62M	58.65M	690.17M	14.66M	45.71M	71.71M	6.18M	-794K	-20.03M	-2.02B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.88M	9.12M	49.72M	-15.29M	-16.77M	-37.76M	-50.03M	-59.05M	-52.51M	-12.96M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	60.53M	184.48M	-204.01M	262.74M	632.59M	-311.98M	568.48M	892.11M	449M	249.07M
FCF Margin %	0.08%	0.17%	-0.13%	0.14%	0.29%	-0.12%	0.19%	0.26%	0.12%	0.06%
FCF Growth %	38.37%	2.05%	-2.11%	2.29%	1.41%	-1.49%	2.82%	0.57%	-0.5%	-0.45%
FCF per Share	0.32	0.95	-1.00	1.22	2.91	-1.43	2.56	3.98	1.99	1.18
FCF Conversion (FCF/Net Income)	13.25x	2.92x	0.30x	3.07x	1.59x	0.42x	0.79x	2.85x	0.83x	10.28x
Interest Paid	12.75M	7.22M	314K	268K	239K	0	396K	0	0	0
Taxes Paid	62K	927K	6.3M	5.42M	33.55M	70.71M	67.73M	136.24M	378.21M	373.06M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	14.59%	35.29%	-30.55%	6.16%	19.76%	-11.35%	29.73%	8.37%	12.5%	0.76%
Return on Invested Capital (ROIC)	18.49%	35.75%	-30.12%	15.01%	38.95%	-18.28%	32.94%	27.95%	28.13%	3.15%
Gross Margin	93.44%	90.59%	92.83%	93.22%	93.18%	93.94%	93.73%	92.54%	91.47%	91.09%
Net Margin	0.87%	9.43%	-20.38%	5.82%	20.7%	-11.09%	31.76%	10.04%	16.17%	0.77%
Debt / Equity	3.62x	1.55x	0.01x	0.02x	0.02x	0.02x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	1.11x	4.23x	-34.16x	100.71x	227.33x	-110.53x	334.14x	224.89x	255.50x	35.15x
FCF Conversion	13.25x	2.92x	0.30x	3.07x	1.59x	0.42x	0.79x	2.85x	0.83x	10.28x
Revenue Growth	47.36%	46.7%	38.93%	22.5%	14.71%	23.53%	11.98%	13.67%	8.87%	14.76%

Revenue by Segment

	2013	2014	2016	2017	2018	2019	2020	2021	2022	2024
J A K A F I	28.3M	49M	852.8M	1.1B	1.58B	1.91B	2.22B	337.99M	2.74B	3.21B
J A K A F I Growth	-	73.14%	1640.41%	28.99%	43.79%	20.82%	15.95%	-84.75%	710.91%	17.15%
OPZELURA	-	-	-	-	-	-	-	4.91M	128.74M	508.29M
OPZELURA Growth	-	-	-	-	-	-	-	-	2521.89%	294.84%
Olumiant Royalty	-	-	-	-	40.09M	80.42M	110.92M	220.88M	134.55M	135.57M
Olumiant Royalty Growth	-	-	-	-	-	100.63%	37.92%	99.13%	-39.08%	0.76%
M I N J U V I	-	-	-	-	-	-	-	68.53M	19.65M	119.24M
M I N J U V I Growth	-	-	-	-	-	-	-	-	-71.32%	506.68%
I C L U S I G	-	-	29.6M	66.9M	79.94M	89.95M	105M	4.67M	105.84M	114.32M
I C L U S I G Growth	-	-	-	126.01%	19.49%	12.53%	16.73%	-95.55%	2167.31%	8.01%
PEMAZYRE Royalty Revenues	-	-	-	-	-	-	25.88M	109.39M	84.65M	83.92M
PEMAZYRE Royalty Revenues Growth	-	-	-	-	-	-	-	322.64%	-22.62%	-0.86%
Milestone And Contract Revenue	-	-	-	-	180M	77.5M	205M	95M	165M	43M
Milestone And Contract Revenue Growth	-	-	-	-	-	-56.94%	164.52%	-53.66%	73.68%	-73.94%
Tabrecta Royalty Revenues	-	-	-	-	-	-	4.14M	10.39M	15.41M	22.75M
Tabrecta Royalty Revenues Growth	-	-	-	-	-	-	-	150.70%	48.34%	47.60%
ZYNYZ	-	-	-	-	-	-	-	-	-	3.19M
ZYNYZ Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2013	2014	2016	2017	2018	2019	2020	2021	2022	2024
U [S]	-	-	-	-	-	-	2.6B	2.9B	-	4B
U [S] Growth	-	-	-	-	-	-	-	11.54%	-	-
Europe	-	-	29.6M	66.9M	79.9M	90M	105M	124.1M	147M	260.4M
Europe Growth	-	-	-	126.01%	19.43%	12.64%	16.67%	18.19%	18.45%	77.14%
UNITED STATES	-	-	-	-	-	-	-	-	3.2B	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Incyte Corporation (INCY) reported $4.81B in revenue for fiscal year 2024. This represents a 4996% increase from $94.5M in 2011.

Incyte Corporation (INCY) grew revenue by 14.8% over the past year. This is steady growth.

Yes, Incyte Corporation (INCY) is profitable, generating $1.19B in net income for fiscal year 2024 (0.8% net margin).

Dividend & Returns

Incyte Corporation (INCY) has a return on equity (ROE) of 0.8%. This is below average, suggesting room for improvement.

Incyte Corporation (INCY) generated $1.20B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Incyte Corporation (INCY) 10-Year Financial Performance & Capital Metrics

INCY • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $4.24B +14.8%
EBITDA $169M -76.9%
Net Income $33M -94.5%
EPS (Diluted) 0.15 -94.3%
Gross Margin 91.09% -0.4%
EBITDA Margin 3.99% -79.9%
Operating Margin 1.89% -89.3%
Net Margin 0.77% -95.2%
ROE 0.76% -94.0%
ROIC 3.15% -88.8%
Debt/Equity 0.01 +71.2%
Interest Coverage 35.15 -86.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 81 (top 19%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 14.5%
✓Share count reduced 6.8% through buybacks

✗Weaknesses

✗Profits declining 40.8% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.56%

5Y14.46%

3Y12.41%

TTM18.09%

Profit (Net Income) CAGR

10Y-

5Y-40.76%

3Y-67.48%

TTM3559.21%

EPS CAGR

10Y-

5Y-40.73%

3Y-67.25%

TTM4164.29%

ROCE

10Y Avg6.96%

5Y Avg7.62%

3Y Avg9.38%

Latest1.72%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	753.75M	1.11B	1.54B	1.88B	2.16B	2.67B	2.99B	3.39B	3.7B	4.24B
Revenue Growth %	0.47%	0.47%	0.39%	0.23%	0.15%	0.24%	0.12%	0.14%	0.09%	0.15%
Cost of Goods Sold+	49.41M	104.01M	110.16M	127.59M	147.28M	161.63M	187.34M	253.35M	315.15M	377.72M
COGS % of Revenue	0.07%	0.09%	0.07%	0.07%	0.07%	0.06%	0.06%	0.07%	0.09%	0.09%
Gross Profit+	704.34M	1B	1.43B	1.75B	2.01B	2.51B	2.8B	3.14B	3.38B	3.86B
Gross Margin %	0.93%	0.91%	0.93%	0.93%	0.93%	0.94%	0.94%	0.93%	0.91%	0.91%
Gross Profit Growth %	0.51%	0.42%	0.42%	0.23%	0.15%	0.25%	0.12%	0.12%	0.08%	0.14%
Operating Expenses+	653.69M	837.69M	1.66B	1.6B	1.59B	2.75B	2.16B	2.54B	2.73B	3.78B
OpEx % of Revenue	0.87%	0.76%	1.08%	0.85%	0.74%	1.03%	0.72%	0.75%	0.74%	0.89%
Selling, General & Admin	174.17M	255.83M	335.61M	400.94M	435.68M	516.9M	703.22M	955.78M	1.1B	1.18B
SG&A % of Revenue	0.23%	0.23%	0.22%	0.21%	0.2%	0.19%	0.24%	0.28%	0.3%	0.28%
Research & Development	479.51M	581.86M	1.33B	1.2B	1.15B	2.22B	1.46B	1.59B	1.63B	2.61B
R&D % of Revenue	0.64%	0.53%	0.86%	0.64%	0.53%	0.83%	0.49%	0.47%	0.44%	0.61%
Other Operating Expenses	0	0	0	0	0	12.52M	0	0	0	0
Operating Income+	50.65M	164.02M	-235.68M	155.4M	421.69M	-240.29M	637.54M	599.56M	651.77M	80.14M
Operating Margin %	0.07%	0.15%	-0.15%	0.08%	0.2%	-0.09%	0.21%	0.18%	0.18%	0.02%
Operating Income Growth %	11.54%	2.24%	-2.44%	1.66%	1.71%	-1.57%	3.65%	-0.06%	0.09%	-0.88%
EBITDA+	95.53M	222.44M	-183.5M	210.37M	476.22M	-188.48M	695.38M	667.42M	734.43M	169.39M
EBITDA Margin %	0.13%	0.2%	-0.12%	0.11%	0.22%	-0.07%	0.23%	0.2%	0.2%	0.04%
EBITDA Growth %	1.61%	1.33%	-1.82%	2.15%	1.26%	-1.4%	4.69%	-0.04%	0.1%	-0.77%
D&A (Non-Cash Add-back)	44.88M	58.42M	52.18M	54.97M	54.53M	51.81M	57.84M	67.86M	82.66M	89.25M
EBIT	53.16M	146.15M	-305.39M	116.89M	488.65M	-230.04M	572.35M	531.78M	836.77M	318.91M
Net Interest Income+	-40.31M	-34.13M	-6.9M	-1.54M	-1.85M	-2.17M	-1.91M	-2.67M	-2.55M	126.43M
Interest Income	5.29M	4.61M	0	0	0	0	0	0	0	128.71M
Interest Expense	45.6M	38.74M	6.9M	1.54M	1.85M	2.17M	1.91M	2.67M	2.55M	2.28M
Other Income/Expense	-43.09M	-56.62M	-76.61M	-40.05M	65.1M	8.07M	-67.09M	-70.45M	182.44M	236.49M
Pretax Income+	7.56M	107.4M	-312.29M	115.35M	486.79M	-232.22M	570.44M	529.12M	834.22M	316.63M
Pretax Margin %	0.01%	0.1%	-0.2%	0.06%	0.23%	-0.09%	0.19%	0.16%	0.23%	0.07%
Income Tax+	1.02M	3.18M	852K	5.85M	39.88M	63.48M	-378.14M	188.46M	236.62M	284.01M
Effective Tax Rate %	0.86%	0.97%	1%	0.95%	0.92%	1.27%	1.66%	0.64%	0.72%	0.1%
Net Income+	6.53M	104.22M	-313.14M	109.49M	446.91M	-295.7M	948.58M	340.66M	597.6M	32.62M
Net Margin %	0.01%	0.09%	-0.2%	0.06%	0.21%	-0.11%	0.32%	0.1%	0.16%	0.01%
Net Income Growth %	1.13%	14.96%	-4%	1.35%	3.08%	-1.66%	4.21%	-0.64%	0.75%	-0.95%
Net Income (Continuing)	6.53M	104.22M	-313.14M	109.49M	446.91M	-295.7M	948.58M	340.66M	597.6M	32.62M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.03	0.54	-1.53	0.51	2.05	-1.36	4.27	1.52	2.65	0.15
EPS Growth %	1.1%	17%	-3.83%	1.33%	3.02%	-1.66%	4.14%	-0.64%	0.74%	-0.94%
EPS (Basic)	0.04	0.55	-1.53	0.52	2.08	-1.36	4.30	1.53	2.67	0.16
Diluted Shares Outstanding	187.3M	194.13M	204.58M	215.63M	217.66M	218.07M	222.07M	223.96M	225.93M	210.53M
Basic Shares Outstanding	179.6M	187.87M	204.58M	212.38M	214.91M	218.07M	220.43M	222M	223.63M	207.11M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	842.38M	994.18M	1.5B	1.83B	2.48B	2.36B	3.12B	4.09B	4.65B	3.24B
Cash & Short-Term Investments	707.78M	808.55M	1.17B	1.44B	2.12B	1.8B	2.35B	3.24B	3.66B	2.16B
Cash Only	521.44M	652.34M	899.51M	1.16B	1.83B	1.51B	2.06B	2.95B	3.21B	1.69B
Short-Term Investments	186.34M	156.2M	270.14M	274.34M	284.87M	288.37M	290.75M	287.54M	442.67M	470.26M
Accounts Receivable	114.45M	148.76M	266.3M	307.6M	308.81M	481.99M	616.3M	644.88M	743.56M	853.15M
Days Sales Outstanding	55.42	49.11	63.27	59.66	52.21	65.97	75.33	69.34	73.44	73.42
Inventory	1.78M	4.11M	6.48M	6.97M	11.4M	16.43M	27.9M	41.99M	62.97M	58.87M
Days Inventory Outstanding	13.17	14.41	21.48	19.93	28.25	37.09	54.37	60.5	72.93	56.89
Other Current Assets	516K	0	0	0	0	0	0	167.01M	182.83M	168.91M
Total Non-Current Assets+	165.06M	644.42M	797.73M	813.51M	945.26M	1.2B	1.81B	1.75B	2.14B	2.21B
Property, Plant & Equipment	86.01M	167.68M	259.76M	319.75M	406.63M	588.08M	751.47M	765.61M	777.05M	794.21M
Fixed Asset Turnover	8.76x	6.59x	5.91x	5.89x	5.31x	4.53x	3.97x	4.43x	4.76x	5.34x
Goodwill	0	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M	155.59M
Intangible Assets	0	270.44M	236.9M	215.36M	193.83M	172.29M	150.75M	129.22M	123.55M	113.8M
Long-Term Investments	35.25M	31.99M	134.36M	99.2M	133.66M	222.3M	221.27M	133.68M	187.72M	18.81M
Other Non-Current Assets	43.81M	18.72M	11.12M	23.6M	55.56M	60.71M	68.06M	106.1M	260.92M	360.8M
Total Assets+	1.01B	1.64B	2.3B	2.65B	3.43B	3.56B	4.93B	5.84B	6.78B	5.44B
Asset Turnover	0.75x	0.67x	0.67x	0.71x	0.63x	0.75x	0.61x	0.58x	0.54x	0.78x
Asset Growth %	0.21%	0.63%	0.41%	0.15%	0.3%	0.04%	0.39%	0.18%	0.16%	-0.2%
Total Current Liabilities+	168.01M	273.5M	375.4M	425.28M	513.34M	631.2M	854.31M	1.16B	1.24B	1.64B
Accounts Payable	30.09M	75.6M	67.67M	103.83M	83.65M	98.77M	172.11M	277.55M	109.6M	197.47M
Days Payables Outstanding	222.23	265.29	224.22	297.02	207.3	223.03	335.34	399.86	126.94	190.82
Short-Term Debt	0	0	7.39M	0	18.3M	0	0	0	0	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	38.12M	70.44M	158.88M	171.36M	226.72M	260.06M	328.26M	435.86M	545.01M	724.83M
Current Ratio	5.01x	3.64x	4.01x	4.31x	4.83x	3.74x	3.65x	3.54x	3.75x	1.97x
Quick Ratio	5.00x	3.62x	3.99x	4.29x	4.81x	3.71x	3.62x	3.50x	3.69x	1.94x
Cash Conversion Cycle	-153.63	-201.78	-139.48	-217.43	-126.83	-119.97	-205.64	-270.02	19.43	-60.5
Total Non-Current Liabilities+	668.28M	945.63M	296.56M	294.52M	315M	318.45M	309.04M	313.79M	351.89M	354.85M
Long-Term Debt	619.89M	651.48M	16.61M	17.43M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	31.92M	32.57M	31.63M	30.08M	29.16M	33.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	48.38M	294.15M	279.95M	277.08M	283.09M	285.88M	277.41M	283.7M	322.73M	321.31M
Total Liabilities	836.28M	1.22B	671.95M	719.79M	828.34M	949.65M	1.16B	1.47B	1.59B	2B
Total Debt+	619.89M	651.48M	24M	36.13M	60.23M	47.53M	44.82M	41.46M	38.29M	43.54M
Net Debt	98.45M	-862K	-875.51M	-1.13B	-1.77B	-1.47B	-2.01B	-2.91B	-3.18B	-1.64B
Debt / Equity	3.62x	1.55x	0.01x	0.02x	0.02x	0.02x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	6.49x	2.93x	-	0.17x	0.13x	-	0.06x	0.06x	0.05x	0.26x
Net Debt / EBITDA	1.03x	-0.00x	-	-5.36x	-3.72x	-	-2.89x	-4.36x	-4.32x	-9.71x
Interest Coverage	1.11x	4.23x	-34.16x	100.71x	227.33x	-110.53x	334.14x	224.89x	255.50x	35.15x
Total Equity+	171.16M	419.47M	1.63B	1.93B	2.6B	2.61B	3.77B	4.37B	5.19B	3.45B
Equity Growth %	3.1%	1.45%	2.89%	0.18%	0.35%	0%	0.44%	0.16%	0.19%	-0.34%
Book Value per Share	0.91	2.16	7.97	8.93	11.94	11.97	16.98	19.51	22.97	16.38
Total Shareholders' Equity	171.16M	419.47M	1.63B	1.93B	2.6B	2.61B	3.77B	4.37B	5.19B	3.45B
Common Stock	187K	189K	211K	213K	216K	219K	221K	223K	224K	193K
Retained Earnings	-1.78B	-1.67B	-1.99B	-1.88B	-1.43B	-1.73B	-777.87M	-437.21M	160.38M	-1.07B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-809K	-2.89M	-7.01M	-10.16M	-15.54M	-15.36M	-19.45M	15.07M	13.11M	-13.12M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	86.54M	304.76M	-92.99M	336.23M	710.66M	-124.6M	749.49M	969.94M	496.49M	335.34M
Operating CF Margin %	0.11%	0.28%	-0.06%	0.18%	0.33%	-0.05%	0.25%	0.29%	0.13%	0.08%
Operating CF Growth %	2.3%	2.52%	-1.31%	4.62%	1.11%	-1.18%	7.02%	0.29%	-0.49%	-0.32%
Net Income	6.53M	104.22M	-313.14M	109.49M	446.91M	-295.7M	948.58M	340.66M	597.6M	32.62M
Depreciation & Amortization	44.88M	58.42M	52.18M	54.97M	54.53M	51.81M	57.84M	67.86M	82.66M	89.25M
Stock-Based Compensation	69.87M	96.2M	133.06M	148.15M	166.59M	177.88M	183.01M	188.42M	215.89M	266.06M
Deferred Taxes	1.71M	3.26M	91.16M	-459K	-377K	-350K	-465.6M	57.09M	-158.9M	-85.55M
Other Non-Cash Items	-1.61M	17.89M	7.99M	70.61M	-14.29M	13.51M	40.23M	117.11M	7.89M	-105.28M
Working Capital Changes	-34.85M	24.75M	-64.23M	-46.54M	57.3M	-71.74M	-14.57M	198.81M	-248.65M	138.24M
Change in Receivables	-56.52M	-23.95M	-117.54M	-41.3M	-1.21M	-173.19M	-134.31M	-28.58M	-98.68M	-111.59M
Change in Inventory	98K	4.05M	4.85M	4.04M	-6.1M	-19.47M	-20.96M	-67.5M	-170.15M	-127.63M
Change in Payables	5.62M	43.76M	-7.93M	36.16M	-20.18M	15.12M	73.34M	105.44M	-167.94M	88.16M
Cash from Investing+	-105.01M	-232.49M	-349.98M	-86.42M	-87.45M	-269M	-207.7M	-78.54M	-207.68M	157.52M
Capital Expenditures	-26M	-120.28M	-111.02M	-73.48M	-78.06M	-187.38M	-181.01M	-77.83M	-47.49M	-86.26M
CapEx % of Revenue	0.03%	0.11%	0.07%	0.04%	0.04%	0.07%	0.06%	0.02%	0.01%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-26M	30.64M	-111.02M	-73.48M	-78.06M	-187.38M	-181.01M	-709K	-47.49M	-13.9M
Cash from Financing+	87.62M	58.65M	690.17M	14.66M	45.71M	71.71M	6.18M	-794K	-20.03M	-2.02B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.88M	9.12M	49.72M	-15.29M	-16.77M	-37.76M	-50.03M	-59.05M	-52.51M	-12.96M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	60.53M	184.48M	-204.01M	262.74M	632.59M	-311.98M	568.48M	892.11M	449M	249.07M
FCF Margin %	0.08%	0.17%	-0.13%	0.14%	0.29%	-0.12%	0.19%	0.26%	0.12%	0.06%
FCF Growth %	38.37%	2.05%	-2.11%	2.29%	1.41%	-1.49%	2.82%	0.57%	-0.5%	-0.45%
FCF per Share	0.32	0.95	-1.00	1.22	2.91	-1.43	2.56	3.98	1.99	1.18
FCF Conversion (FCF/Net Income)	13.25x	2.92x	0.30x	3.07x	1.59x	0.42x	0.79x	2.85x	0.83x	10.28x
Interest Paid	12.75M	7.22M	314K	268K	239K	0	396K	0	0	0
Taxes Paid	62K	927K	6.3M	5.42M	33.55M	70.71M	67.73M	136.24M	378.21M	373.06M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	14.59%	35.29%	-30.55%	6.16%	19.76%	-11.35%	29.73%	8.37%	12.5%	0.76%
Return on Invested Capital (ROIC)	18.49%	35.75%	-30.12%	15.01%	38.95%	-18.28%	32.94%	27.95%	28.13%	3.15%
Gross Margin	93.44%	90.59%	92.83%	93.22%	93.18%	93.94%	93.73%	92.54%	91.47%	91.09%
Net Margin	0.87%	9.43%	-20.38%	5.82%	20.7%	-11.09%	31.76%	10.04%	16.17%	0.77%
Debt / Equity	3.62x	1.55x	0.01x	0.02x	0.02x	0.02x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	1.11x	4.23x	-34.16x	100.71x	227.33x	-110.53x	334.14x	224.89x	255.50x	35.15x
FCF Conversion	13.25x	2.92x	0.30x	3.07x	1.59x	0.42x	0.79x	2.85x	0.83x	10.28x
Revenue Growth	47.36%	46.7%	38.93%	22.5%	14.71%	23.53%	11.98%	13.67%	8.87%	14.76%

Revenue by Segment

	2013	2014	2016	2017	2018	2019	2020	2021	2022	2024
J A K A F I	28.3M	49M	852.8M	1.1B	1.58B	1.91B	2.22B	337.99M	2.74B	3.21B
J A K A F I Growth	-	73.14%	1640.41%	28.99%	43.79%	20.82%	15.95%	-84.75%	710.91%	17.15%
OPZELURA	-	-	-	-	-	-	-	4.91M	128.74M	508.29M
OPZELURA Growth	-	-	-	-	-	-	-	-	2521.89%	294.84%
Olumiant Royalty	-	-	-	-	40.09M	80.42M	110.92M	220.88M	134.55M	135.57M
Olumiant Royalty Growth	-	-	-	-	-	100.63%	37.92%	99.13%	-39.08%	0.76%
M I N J U V I	-	-	-	-	-	-	-	68.53M	19.65M	119.24M
M I N J U V I Growth	-	-	-	-	-	-	-	-	-71.32%	506.68%
I C L U S I G	-	-	29.6M	66.9M	79.94M	89.95M	105M	4.67M	105.84M	114.32M
I C L U S I G Growth	-	-	-	126.01%	19.49%	12.53%	16.73%	-95.55%	2167.31%	8.01%
PEMAZYRE Royalty Revenues	-	-	-	-	-	-	25.88M	109.39M	84.65M	83.92M
PEMAZYRE Royalty Revenues Growth	-	-	-	-	-	-	-	322.64%	-22.62%	-0.86%
Milestone And Contract Revenue	-	-	-	-	180M	77.5M	205M	95M	165M	43M
Milestone And Contract Revenue Growth	-	-	-	-	-	-56.94%	164.52%	-53.66%	73.68%	-73.94%
Tabrecta Royalty Revenues	-	-	-	-	-	-	4.14M	10.39M	15.41M	22.75M
Tabrecta Royalty Revenues Growth	-	-	-	-	-	-	-	150.70%	48.34%	47.60%
ZYNYZ	-	-	-	-	-	-	-	-	-	3.19M
ZYNYZ Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2013	2014	2016	2017	2018	2019	2020	2021	2022	2024
U [S]	-	-	-	-	-	-	2.6B	2.9B	-	4B
U [S] Growth	-	-	-	-	-	-	-	11.54%	-	-
Europe	-	-	29.6M	66.9M	79.9M	90M	105M	124.1M	147M	260.4M
Europe Growth	-	-	-	126.01%	19.43%	12.64%	16.67%	18.19%	18.45%	77.14%
UNITED STATES	-	-	-	-	-	-	-	-	3.2B	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Incyte Corporation (INCY) reported $4.81B in revenue for fiscal year 2024. This represents a 4996% increase from $94.5M in 2011.

Incyte Corporation (INCY) grew revenue by 14.8% over the past year. This is steady growth.

Yes, Incyte Corporation (INCY) is profitable, generating $1.19B in net income for fiscal year 2024 (0.8% net margin).

Dividend & Returns

Incyte Corporation (INCY) has a return on equity (ROE) of 0.8%. This is below average, suggesting room for improvement.

Incyte Corporation (INCY) generated $1.20B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.